Simplify Logo

Full-Time

Senior Bioprocessing Associate

Downstream

Posted on 5/24/2024

Umoja Biopharma

Umoja Biopharma

201-500 employees

Develops in vivo CAR T-cell therapies

Hardware
AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$36.57 - $44Hourly

Mid

Lafayette, CO, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree in a related biotechnology or life-sciences field with 4 years of cGMP manufacturing experience in the pharmaceutical and/or biologics field; OR Associate’s degree in a related biotechnology or life-sciences field with 2 years of cGMP manufacturing experience in the pharmaceutical and/or biologics field ; OR equivalent combination of education and experience will be considered.
Responsibilities
  • Assist in the development and implementation of compliant and technically sound programs and systems in support of GMP manufacturing facility Operational Readiness
  • Actively participate in the receipt of internal technology transfer of novel cell/gene therapy manufacturing processes at various scales.
  • Author and review controlled documents and standard operating procedures on behalf of Manufacturing Operations
  • Observe, participate, and perform in internal technology transfer runs from MSAT to Manufacturing
  • Perform activities related to the introduction of new raw materials, bulk drug substance, and drug product specifications from draft through approval
  • Perform equipment cleanings, as required, per routine maintenance events, and pre/post process requirements
  • Adhere to Standard Operating Procedures, good manufacturing practices, and good documentation practices
  • Perform and participate in manufacturing equipment, process, and system validation activities including Environmental Monitoring Performance Qualification (EMPQ), and IQ/OQ/PQ (As applicable) of Manufacturing equipment and systems
  • Perform aseptic manufacture of lentiviral products in an aseptic clean-room environment (ISO5, ISO7, ISO8, ISO9)
  • Maintain inventory and perform stocking activities for gowning, cleaning, and consumable materials to ensure sufficient inventory is available to support manufacturing operations
  • Perform material management activities related to the weigh/dispense and kitting of Bill of Materials items
  • Perform solution and buffer prep operations in a clean-room environment (ISO9)
  • Other duties as needed

Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for long-lasting remissions. The company primarily targets patients with solid tumors and hematological cancers that have not responded to other treatments. Its business model is based on developing and commercializing a proprietary CAR T-cell gene therapy platform that is scalable and can treat cancers at various stages. By producing off-the-shelf therapies in-house, Umoja can distribute its treatments more efficiently than those requiring individual customization. The goal is to enhance cancer treatment through effective use of the immune system.

Company Stage

Series B

Total Funding

$271M

Headquarters

Seattle, Washington

Founded

2019

Growth & Insights
Headcount

6 month growth

3%

1 year growth

17%

2 year growth

46%
Simplify Jobs

Simplify's Take

What believers are saying

  • The collaboration with AbbVie, valued at up to $1.44 billion, provides substantial financial backing and validation of Umoja's technology.
  • Umoja's appointment of experienced executives like Britton Russell as CFO indicates strong leadership capable of guiding the company through growth phases.
  • Being recognized as one of the thriving biotechs in Seattle underscores Umoja's prominence and potential in the biotech industry.

What critics are saying

  • The success of Umoja's in vivo CAR T-cell therapies is still contingent on clinical trial outcomes, which carry inherent uncertainties.
  • The competitive landscape in immunotherapy is intense, with numerous companies vying for market share, which could impact Umoja's growth.

What makes Umoja Biopharma unique

  • Umoja Biopharma's in vivo approach to reprogramming T cells is a significant departure from traditional ex vivo methods, offering a potentially more efficient and scalable solution.
  • Their proprietary CAR T-cell gene therapy platform is designed to be off-the-shelf, allowing for faster production and distribution compared to customized therapies.
  • Strategic partnerships with major players like AbbVie highlight Umoja's innovative edge and potential for significant market impact.
INACTIVE